The roles of carboxylesterase and CYP isozymes on the in vitro metabolism of T-2 toxin by Ni-Ni Lin et al.
Lin et al. Military Medical Research  (2015) 2:13 
DOI 10.1186/s40779-015-0041-6RESEARCH Open AccessThe roles of carboxylesterase and CYP
isozymes on the in vitro metabolism of T-2
toxin
Ni-Ni Lin, Jia Chen, Bin Xu, Xia Wei, Lei Guo* and Jian-Wei Xie*Abstract
Background: T-2 toxin poses a great threat to human health because it has the highest toxicity of the currently
known trichothecene mycotoxins. To understand the in vivo toxicity and transformation mechanism of T-2 toxin, we
investigated the role of one kind of principal phase I drug-metabolizing enzymes (cytochrome P450 [CYP450] enzymes)
on the metabolism of T-2 toxin, which are crucial to the metabolism of endogenous substances and xenobiotics. We
also investigated carboxylesterase, which also plays an important role in the metabolism of toxic substances.
Methods: A chemical inhibition method and a recombinant method were employed to investigate the metabolism
of the T-2 toxin by the CYP450 enzymes, and a chemical inhibition method was used to study carboxylesterase
metabolism. Samples incubated with human liver microsomes were analyzed by high performance liquid
chromatography-triple quadrupole mass spectrometry (HPLC- QqQ MS) after a simple pretreatment.
Results: In the presence of a carboxylesterase inhibitor, only 20 % T-2 toxin was metabolized. When CYP enzyme
inhibitors and a carboxylesterase inhibitor were both present, only 3 % of the T-2 toxin was metabolized. The
contributions of the CYP450 enzyme family to T-2 toxin metabolism followed the descending order CYP3A4, CYP2E1,
CYP1A2, CYP2B6 or CYP2D6 or CYP2C19.
Conclusion: Carboxylesterase and CYP450 enzymes are of great importance in T-2 toxin metabolism, in which
carboxylesterase is predominant and CYP450 has a subordinate role. CYP3A4 is the principal member of the CYP450
enzyme family responsible for T-2 toxin metabolism. The primary metabolite produced by carboxylesterase is HT-2, and the
main metabolite produced by CYP 3A4 is 3′-OH T-2. The different metabolites show different toxicities. Our results will
provide useful data concerning the toxic mechanism, the safety evaluation, and the health risk assessment of T-2 toxin.
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T-2 toxin (4β, 15-diacetoxy-8α-(3-methylbutyryloxy)-3α-
hydroxy-12, 13-epoxytrichothece-9-ene) is a toxic second-
ary metabolite produced by various species of Fusarium
growing on cereal grains [1, 2]. Because it has extensively
contaminated crops and cereals worldwide, animals and
humans have a high potential of intoxication from con-
taminated food and feed. Typical symptoms of intoxica-
tion induced by T-2 toxin are feed refusal, weight loss and
vomiting, which are related to its inhibitory effects on* Correspondence: guolei@bmi.ac.cn; xiejw@bmi.ac.cn
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pressive and cytotoxic effects [3, 4].
T-2 toxin is rapidly metabolized in vivo, for example,
its half-life is only 21 ± 5 min after the intramuscular
injection of 0.4 mg/kg to dogs [5]. Ten or more metabo-
lites have been deduced [6] and the metabolic pathways for
T-2 toxin include hydrolysis, hydroxylation, de-epoxidation,
glucuronidation and acetylation [7].
Because of their important role in toxin metabolism,
drug-metabolizing enzymes have attracted much atten-
tion in studies aimed at gaining an understanding of tox-
icity. The cytochrome P450 (CYP450) superfamily is the
major phase I metabolic enzymes in the liver (the princi-
pal organ responsible for drug metabolism), and thesee distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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drug metabolism [8]. These enzymes are crucial for the
metabolism of foreign chemicals, including drugs, car-
cinogens, pollutants, pesticides and herbal compounds,
as well as endogenous substances, including steroids,
fatty acids and cholesterol [9]. The metabolic effect of
the CYP450 enzymes on T-2 toxin has also aroused recent
interest. Meissonnier et al. [10] found reduced expression
of CYP1A proteins and CYP1A-related activities (ethoxyr-
esorufin O-deethylation and benzo-(a)-pyrene hydroxyl-
ation) in pigs after the intake of feed contaminated with
T-2 toxin. Osselaere et al. [11] demonstrated significant
down-regulation of CYP1A4, CYP1A5 and CYP3A37
mRNA expression when broilers were fed a diet contami-
nated with T-2 toxin.
Carboxylesterase is another important type of phase I
enzyme that metabolizes toxic substances [12, 13]. Johnsen
et al. [14] found that T-2 toxin was rapidly hydrolyzed into
the main metabolite HT-2 toxin by carboxylesterase in a
rat liver microsomal fraction.
However, the effects of phase I drug-metabolizing
CYP450 and carboxylesterase enzymes in the metabol-
ism of T-2 toxin in humans have yet to be demonstrated.
To address this issue in this study, human liver micro-
somes (HLMs) were used to investigate the metabolism
of T-2 toxin by CYP450 enzymes and carboxylesterase
employing a chemical inhibition and a recombinant
method. We believe the results can provide information
about the mechanism of toxicity of the T-2 toxin and
other structurally similar toxins.
Methods
Chemicals and reagents
T-2 toxin, HT-2 toxin, neosolaniol (NEO), acetyl T-2,
T-2 triol, T-2 tetraol and zearalanone (ZAN) with a
purities greater than 98 %, bis (4-nitrophenyl) phosphate
(BNPP), ethyleneglycol-bis (2-aminoethylether) -tetraacetic
acid (EGTA), tetraisopropylpyrophosphamide (iso-OM
PA), phenacetin, dextromethorphan, tolbutamide, α-
naphthoflavone, sulfaphenazole, quinidine and tranylcy-
promine of analytical grade were purchased from Sigma
Aldrich (St. Louis, MO, USA). We synthesized 3′-OH T-2
(purity of 99 %) in our laboratory. HPLC grade methanol
and acetonitrile were obtained from DUKSAN (Sungkok,
Korea). All other reagents were of analytical grade or
better and purchased from Sino Pharm chemical re-
agent Co. Ltd (Beijing, China). Sterilized ultrapure
water was generated with a Milli-Qultrapure water
system (Millipore, Billerica, MA, USA). Human liver
microsomes and nicotinamide adenine dinucleotide
phosphate (NADPH) were purchased from Beijing
Dingguo Changsheng Biotechnology Co., Ltd. (Beijing,
China). CYP450 enzymes and S-mephenytoin were
purchased from BD Gentest (Woburn, MA, USA).Midazolam and ketoconazole were purchased from the
National Institutes for Food and Drug Control (NIFDC,
Beijing, China).
All samples were separated in an Agilent 1200 HPLC
system equipped with a binary pump, an Agilent control
union, a degasser, and an auto sampler, and then de-
tected by an Agilent 6430 triple quadrupole mass spec-
trometry (QqQ MS) equipped with an electrospray ion
source (Agilent Co., California, USA). The introduction
of the liquid phase was accomplished with an Agilent
XDB C18 column (50 mm long, 4.6 mm diameter,
1.8 μm particle size, Agilent Co., California, USA) coupled
with a Waters in-line filter kit (Waters Co., Milford, USA).
All data were collected and analyzed by Agilent ChemSta-
tion software with MassHunter acquisition system (ver.
B.04.00).
Inhibitor phenotyping samples [15]
T-2 toxin (50 μL) at a concentration of 10 μmol/L was
pre-incubated with 3 μl BNPP at a concentration of
3 mmol/L (an inhibitor of carboxylesterase), 1 μL EGTA
at a concentration of 1 mmol/L (an inhibitor of paraoxo-
nase), 5 μL iso-OMPA at a concentration 50 μmol/L (an
inhibitor of acetylcholine esterase) with human liver mi-
crosomes at 37 °C for 5 min, respectively. HLM at a con-
centration of 0.5 mg/mL was then added to start the
reaction, and 200 μL solution of 1 mmol/L ZAN in 1:3
methane: acetonitrile was added to stop the reaction
after 30 min.
Chemical inhibition method to determine the
contribution of CYP450 enzymes [15]
The sample group was prepared as follows: 100 μL T-2
toxin at a concentration of 10 μmol/L was pre-incubated
with 80 μL of α-naphthoflavone at a concentration of
10 μmol/L (an inhibitor of CYP1A2), sulfaphenazole at a
concentration of 40 μmol/L (an inhibitor of CYP2C9),
tranylcypromine at a concentration of 400 μmol/L (an
inhibitor of CYP2C19), quinidine at a concentration of
10 μmol/L (an inhibitor of CYP2D6), or ketoconazole at
a concentration of 10 μmol/L (an inhibitor of CYP3A4),
respectively, in HLMs at 37 °C for 5 min. NADPH
(20 μl) at a concentration of 1 mmol/L was then added
to start the reaction, and a solution of 1 mmol/L ZAN
in 1:3 methane: acetonitrile was added to stop the reac-
tion after 30 min.
The inhibitor group was prepared as follows: all proce-
dures were same as for the sample group, except that
the carboxylesterase inhibitor BNPP was added at the
beginning. For the positive control group, all procedures
were same as the sample group, except that no isozyme
inhibitor was added. For the negative control group, all
procedures were same as the sample group, except that
no inhibitor was added.
Table 1 Parameters for the analytes and internal standard in
HPLC-QqQ MS
Analytes Ion pairs (m/z) Fragmentor (V) Collision (V)
NEO 400.1/185.0 85 15
3'-OH T-2 500.2/185.0 100 20
Triol 383.0/215.0 90 2
HT-2 442.2/215.0 95 8
T-2 484.2/185.0 110 15
ZAN (IS) 321.2/190.1 80 18
Acetyl T-2 526.2/287.1 105 10
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tions were terminated, all samples were vortexed for
2 min and then centrifuged at 14,000 r/min for 10 min.
The supernatant was injected in the HPLC-QqQ MS.
Recombinant CYPs test [15]
All the procedures were same as for the sample group,
except that the CYP450 isozyme was used instead of the
liver microsomes. The isozymes included CYP2C19,
CYP3A4, CYP2C9, CYP2A6, CYP2B6, CYP2D6, CYP1A2,
CYP2C8 and CYP2E1, at a concentration of 25 nmol/L.
To determine the effects of NADPH, we used the
same incubation conditions as for the sample group.
Moreover, we added the stop solution at 0, 1, 2, 3, 4, 5,
10, 15, 20, 30 min to stop the reaction.
Statistical analysis
The data were expressed as the mean ± SD and analyzed
by an ANOVA test for independent samples using the
SPSS 11.5 statistical software. The level of significance
was P < 0.05.
HPLC-QqQ MS parameters
The analysis was followed our previously established
method with slight modifications [16]. The separation
was performed on an Agilent XDB C18 column (50 mm
long, 4.6 mm diameter, 1.8 μm particle size) coupled
with a Waters in-line filter kit. The mobile phase A was
5 mmol/L ammonium acetate in water, and the mobile
phase B was 5 mmol/L ammonium acetate in methanol.
The gradient profile was 65 % B held from 0 to 0.5 min,
followed by a linear increase to 100 % B over 3 min that
was held for 2.5 min, then a decrease to 65 % B over
0.1 min that was held for 0.9 min, for a total run time of
7.0 min. The flow rate was 0.6 mL/min, the injection
volume was 5 μl, and the column temperature was set to
50 °C.
The HPLC eluent was transferred by the XDB-C18
chromatographic column after the guard column to an
Agilent triple-quadrupole mass spectrometer (QqQ MS)
in the positive electrospray ionization mode. The capil-
lary voltage was set to 3500 V, the source temperature
was set at 350 °C, and the drying gas was set at 9 L/min.
All of the analytes were measured in the multiple reac-
tion monitoring (MRM) mode. All other parameters
listed in Table 1.
Results and discussion
To investigate the contribution of the CYP450 subfamily
and carboxylesterase on the metabolism of T-2 toxin, we
used chemical inhibition and recombinant methods.
However, besides measuring changes in the T-2 toxin it-
self, we also simultaneously measured six of its principal
metabolites to determine their fluctuation.Method evaluation
First, we established an HPLC-QqQ MS method for
measuring T-2 toxin and its six metabolites in HLMs
with ZAN as the internal standard. Good linearity (R2 >
0.990) in a range from 0.005 to 20.0 μmol/L was
obtained, the limit of detection was between 0.001 and
0.067 μmol/L, and the recovery varied from 82.2 % to
119.1 % with relative standard deviations of 6.5 % to
14.9 %. The method was proved to be rapid, reproducible,
and sensitive and was successfully applied to the metabolic
research of T-2 toxin.
Contribution of different enzymes
To include most types of phase I drug-metabolizing en-
zymes existing in HLMs, we investigated the CYP450
enzymes, carboxylesterase, paraoxonase and acetylcho-
line esterase. We first examined the self-degradation of
T-2 toxin and found that T-2 toxin was stable in phos-
phate buffer for over one hour. We then added NADPH
to activate the CYP450 enzymes, or did not add NADPH
to observe the effects of other enzymes on T-2 toxin
metabolism.
The results are shown in Fig. 1. A common single ex-
ponential decay model used in metabolic stability studies
[17] with the formula of t1/2 = −0.693/ln[(Ct/C0) × 100]
was plotted in Fig. 1, where t is the reaction period, Ct is
the concentration of the parent compound at time t, and
C0 is the initial concentration in the incubation system.
Figure 1 shows that T-2 toxin is rapidly depleted if the
CYP450 enzymes are unactivated, with a t1/2 (NADPH)
of 0.4 min and t1/2 (PBS) of 0.6 min. These data clearly
suggest that other types of enzymes have a greater
contribution to T-2 toxin metabolism than the CYP450
enzymes.
The precise contribution of each type of enzyme other
than CYP450 was determined with a corresponding
chemical inhibitor. The carboxylesterase inhibitor BNPP,
the paraoxonase inhibitor EGTA and the acetylcholine
esterase inhibitor iso-OMPA were added to the incuba-
tion system with T-2 toxin. The results are shown in
Fig. 2, which employs the concentration relationship
Table 2 Different inhibition effects of CYP450 isozymes on T-2
Fig. 1 Semi-logarithm plot of the remaining percentage of the T-2
toxin in HLMs vs incubation time
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to illustrate the effect of each type of enzyme. The initial
concentration of T-2 toxin was 10 μmol/L. More than
80 % T-2 toxin was metabolized when EGTA, iso-
OMPA or no inhibitor was added, but approximately
80 % of the T-2 toxin remained unmetabolized when
BNPP was added. These results demonstrate that EGTA
and iso-OMPA have little influence on T-2 toxin metab-
olism, but BNPP greatly affects T-2 toxin metabolism.
We concluded that carboxylesterase was the predomin-
ant enzyme for T-2 toxin metabolism. The results
confirmed the importance of carboxylesterase in the de-
toxification of trichothecenes as Johnsen et al. [14] con-
cluded. However, Johnsen et al. used rat liver but we
used human liver, so our experiment was more reflective
of human metabolism.
CYP450 enzyme
CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4
play the most important roles in the CYP450 subfamily,Fig. 2 Influence of different enzyme inhibitors on T-2 toxin metabolism.
(1) P< 0.05 compared with no inhibitor groupand they were recommended by the United States Food
and Drug Administration for the evaluation of drug me-
tabolism in humans [18, 19]. In this study, we employed
two methods, a chemical inhibitor method and a recom-
binant method with a normalization approach, to evalu-
ate the effects of the CYP450 isozymes. For the chemical
inhibitor method, we chose five different chemical inhib-
itors of the five important isozymes and CYP2B6. Table 2
shows that, in the presence of the carboxylesterase in-
hibitor BNPP, approximately 3 % T-2 toxin was metabo-
lized when a CYP450 enzyme inhibitor was added. We
also observed the same trend in the concentrations of T-
2 toxin and its principal metabolites. As shown in Fig. 3,
almost all of the T-2 toxin is metabolized without the
CYP450 enzyme inhibitor and BNPP, while T-2 toxin re-
mains in the presence of the CYP450 enzyme inhibitor
and BNPP; in the latter situation, CYP3A4 shows the
highest metabolism ability to T-2 toxin of all six CYP450
isozymes. The major metabolite in the absence of BNPP
was HT-2 and 3′-OH T-2 was produced in the presence
of BNPP.
We also used a recombinant method for the CYP450
subfamily only, by which we could calculate the contri-
bution of each isozyme to T-2 metabolism by using the
metabolic velocity value for the T-2 toxin and the con-
centration of each CYP isozyme (Ccyp) [20], and the
total normalized rate (TNR) [21]. The metabolic velocity
was calculated by the formula Vm = (C0- Ct)/t × Ccyp
(protein), where Vm is the metabolic velocity, t is the re-
action period, Ct is the concentration of the parent com-
pound at time t, and C0 is the initial concentration in
the incubation system where Ccyp was the content of
specific CYP450 in the human liver.
TNR was given by the formula: Percent TNR = (NR/
TNR) × 100 %.toxin metabolism in HLMs










0.19 ± 0.08 107.24 ± 3.16
CYP3A4 Ketonazle 0.27 ± 0.06 112 ± 6.10
CYP 2C9 Sulfaphenazole 0.10 ± 0.04 102.10 ± 0.80
CYP 2D6 Quinidine 0.26 ± 0.06 96.87 ± 7.87
CYP 1A2 α-naphthol 0.14 ± 0.08 99.37 ± 2.68
Negative
control
No inhibitor 0.16 ± 0.07 97.10 ± 8.34
Controla No inhibitor 100 ± 3.86 100 ± 3.86
aThe termination solution was added at the beginning in HLMs and no NADPH
added to active the reaction
Fig. 3 Influence of CYP450 inhibitors on T-2 toxin metabolism. HLM# is T-2 toxin incubated with the HLMs as same as in the sample group except
that all the isozyme inhibitors were added; and HLM## is T-2 toxin incubated with the HLMs the same as in the sample group with BNPP except
that all the inhibitors were added
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the reaction rate for each isoform by the specific CYP450
content in the HLMs. The NRs were then summed to give
the TNR.
Table 3 shows the results, which followed the descend-
ing order of CYP3A4, CYP2E1, CYP1A2, CYP2C9,
CYP2B6 or CYP2D6 or CYP2C19, in which CYP3A4
contributed the most to T-2 toxin metabolism, a value
close to 90 %.
The two methods yielded orders of contribution to T-
2 toxin metabolism that were slightly different, but both
methods indicated that the CYP3A4 isozyme was the
major contributor. Considering that the chemical inhibi-
tor was nonspecific in some cases, meaning that two or
more types of enzymes could be inhibited, the recom-
binant method probably reflects more reliable results.
Wang et al. [22] determined that porcine CYP3A46
mainly converted T-2 toxin to 3'OH T-2, which was fur-
ther confirmed using purified CYP3A46 protein. They
added ketoconazole, which is a potent inhibitor of
CYP3A4-mediated metabolism in humans that has been
widely used as a probe for CYP3A inhibition in other
animal species [23]. As the dosage of ketoconazole in-
creased, the amount of 3'OH T-2 decreased. Recombinant
pig CYP3A22 converted T-2 toxin into 3′-OH T-2 toxinTable 3 Contribution of CYP450 isozyme to T-2 toxin hepatic metab
CYP isozyme type CYP2C19 CYP 3A4 CY
Vm (nmol/T-2/min nmol protein) 0.86 ± 0.02 13.98 ± 3.46 0.4
Percentage of total activity 0.63 89.70 1.7and HT-2 toxin into 3′-OH HT-2 toxin in vitro [24]. Pig
CYP3A22 eliminated T-2 and HT-2 toxins primarily by
3′-hydroxylation of the isovaleryl groups. It was suggested
that CYP3A22 was critical for xenobiotic metabolism and
the endogenous biochemical biotransformation of tricho-
thecene mycotoxin in pigs. CYP1A5 played an important
role in chickens by hydroxylating T-2 toxin to 3′-OH T-2
[25]. CYP3A37 converted T-2 toxin to 3′-OH T-2, and
the T-2 hydroxylation activity of CYP3A37 was strongly
inhibited by ketoconazole. Chicken CYP3A37 can also
catalyze erythromycin N-demethylation, which is another
CYP3A-specific activity. These findings indicate that
chicken CYP3A37 may have a broad substrate spectrum
similar to its human homologue CYP3A4 [26]. The
metabolism of T-2 toxin has been extensively studied in
animals; however, data in HLM and human recombinant
enzymes are sparse. Our results showed CYP3A4 played
major roles in recombinant enzymes in human liver mi-
crosomes, and the 3′-OH T-2 toxin was the correspond-
ing product (Fig. 4). The results were similar to those in
pigs and chickens in which CYP3As-specific activity had
similar effects and the same product was produced.
Chicken CYP1A5 was involved in the metabolism of T-2,
but the type of CYPs was different in human because of
the species difference.olism assessed by the TNR method
P2C9 CYP2B6 CYP2D6 CYP1A2 CYP2E1
7 ± 0.03 1.2 ± .02 1.73 ± 0.03 1.37 ± 0.05 1.41 ± 0.07
2 0.69 0.63 3.01 3.62
Fig. 4 The type and concentration of different T-2 toxin metabolites
with different phenotypes of CYP450 recombinants. * P < 0.05
compared with 37 °C group. The order of T-2 toxin metabolism was
CYP3A4, CYP2D6, CYP2C19, CYP1A2, CYP2C9 at 25 or 37 °C. The
termination solution was added at the beginning when T-2 toxin
was incubated at 25 or 37 °C
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From systematic research on carboxylesterase and
CYP450 enzymes for T-2 toxin metabolism in HLMs,
we concluded that the carboxylesterase plays the primary
role and CYP450 enzymes are subordinate. CYP3A4 was
the major isozyme in CYP450 subfamily that contributed
to T-2 toxin metabolism. The major metabolite was HT-2
with carboxylesterase and 3′-OH T-2 with CYP3A4. Our
results provide useful data about the toxic mechanism of
T-2 toxin.
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